Citigroup
HCAT icon

Citigroup’s Health Catalyst HCAT Stock Holding History

Citigroup’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4 Sell
2
-2,963
-100% -$4.28K ﹤0.01% 5627
2026
Q1 		$3.77K Buy
2,965
+1,435
+94% +$2.7K ﹤0.01% 5315
2025
Q4 		$3.66K Buy
1,530
+609
+66% +$1.67K ﹤0.01% 5334
2025
Q3 		$2.63K Sell
921
-21,839
-96% -$74.8K ﹤0.01% 5414
2025
Q2 		$85.8K Sell
22,760
-21,164
-48% -$83.3K ﹤0.01% 4486
2025
Q1 		$199K Sell
43,924
-4,035
-8% -$21.4K ﹤0.01% 4207
2024
Q4 		$339K Buy
47,959
+3,797
+9% +$30.2K ﹤0.01% 4081
2024
Q3 		$359K Buy
44,162
+27,401
+163% +$198K ﹤0.01% 3942
2024
Q2 		$107K Buy
16,761
+5,500
+49% +$35.3K ﹤0.01% 4175
2024
Q1 		$84.8K Sell
11,261
-27,552
-71% -$251K ﹤0.01% 4365
2023
Q4 		$359K Buy
38,813
+37,748
+3,544% +$308K ﹤0.01% 3622
2023
Q3 		$10.8K Sell
1,065
-33,477
-97% -$400K ﹤0.01% 4524
2023
Q2 		$432K Buy
34,542
+33,019
+2,168% +$393K ﹤0.01% 3473
2023
Q1 		$17.8K Sell
1,523
-139
-8% -$1.77K ﹤0.01% 4548
2022
Q4 		$17.7K Sell
1,662
-1,200
-42% -$11.6K ﹤0.01% 4644
2022
Q3 		$28K Sell
2,862
-4,037
-59% -$53.5K ﹤0.01% 4615
2022
Q2 		$100K Buy
6,899
+2,828
+69% +$48.2K ﹤0.01% 4224
2022
Q1 		$107K Sell
4,071
-11,027
-73% -$313K ﹤0.01% 4382
2021
Q4 		$598K Buy
15,098
+7,652
+103% +$349K ﹤0.01% 3665
2021
Q3 		$372K Sell
7,446
-10,256
-58% -$559K ﹤0.01% 3814
2021
Q2 		$983K Buy
17,702
+13,715
+344% +$731K ﹤0.01% 3242
2021
Q1 		$186K Sell
3,987
-2,932
-42% -$142K ﹤0.01% 4049
2020
Q4 		$301K Buy
6,919
+5,118
+284% +$189K ﹤0.01% 4654
2020
Q3 		$66K Sell
1,801
-5,209
-74% -$177K ﹤0.01% 5404
2020
Q2 		$204K Buy
7,010
+1,113
+19% +$30.8K ﹤0.01% 4996
2020
Q1 		$154K Buy
5,897
+3,882
+193% +$119K ﹤0.01% 4961
2019
Q4 		$70K Buy
2,015
+1,641
+439% +$54.3K ﹤0.01% 6053
2019
Q3 		$11K Buy
+374
New +$14.7K ﹤0.01% 7024

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $239M AUM
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's HCAT Position: Q2 2026 in Review

Citigroup reduced its Health Catalyst (HCAT) stake by 100% in Q2 2026, selling an estimated $4.28K and leaving 2 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #5627.

Citigroup first reported a position in HCAT in Q3 2019 and has held it in 28 quarters since. The position peaked at $983K in Q2 2021. 127 funds tracked by Wall St. Rank hold HCAT as of Q2 2026.

  • Citigroup held 2 shares of Health Catalyst worth $4 as of Q2 2026.
  • Citigroup sold 2,963 Health Catalyst shares in Q2 2026, an estimated $4.28K.
  • Health Catalyst made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5627 holding.
  • Citigroup first reported a position in Health Catalyst in Q3 2019 and has held it in 28 quarters since.
  • Citigroup's Health Catalyst position peaked at $983K in Q2 2021.
  • 127 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.